India, May 7 -- Supernus Pharmaceuticals Inc. (SUPN), Tuesday announced a licensing deal with M8 Pharmaceuticals to commercialize its ADHD drug Qelbree under the latter's trademark in Latin America.
FDA-approved Qelbree is a prescription medicine to treat attention deficit hyperactivity disorder in adults and children of 6 years of age and older. The company also announced that a second phase 4 clinical trial in pre-school-age children with ADHD is expected to begin in January 2024.
Currently, Supernus's stock is trading at $30.82, up 1.31 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....